Exposure of breast cancer cell lines to doxorubicin, docetaxel, and therapy with selective estrogen receptor modulators (SERMs) resulted in selecting a chemoresistant population of cells with increased expression of Notch 1 and Notch 4 [20]. This evidence concerns the gene NOTCH1 and breast cancer.